Recombinant Human ADAM9 His-tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 939-ADB

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
939-ADB-020
Print Quote
Bulk Order
100% Guarantee

Key Product Details

  • R&D Systems HEK293-derived Recombinant Human ADAM9 His-tag Protein (939-ADB)
  • Quality control testing to verify active proteins with lot specific assays by in-house scientists
  • All R&D Systems proteins are covered with a 100% guarantee

Source

HEK293

Accession #

Q13443.1

Structure / Form

Mature form

Conjugate

Unconjugated

Applications

Enzyme Activity

View all ADAM9 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human ADAM9 protein
Ala206-Asp697, with a C-terminal 10-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala206

Predicted Molecular Mass

55 kDa

SDS-PAGE

61-68 kDa, under reducing conditions.

Activity

Measured by its ability to cleave a fluorogenic peptide substrate Mca-PLAQAV-Dpa-RSSSR-NH2 (Catalog # ES003).
The specific activity is >5 pmol/min/μg, as measured under the described conditions.

Scientific Data Images for Recombinant Human ADAM9 His-tag Protein, CF

Recombinant Human ADAM9 His-tag Protein SDS-PAGE.

2 μg/lane of Recombinant Human ADAM9 His-tag Protein (Catalog # 939-ADB) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 61-68 kDa, under reducing conditions.

Formulation, Preparation and Storage

939-ADB
Formulation Supplied as a 0.2 μm filtered solution in MES and NaCl.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: ADAM9

Recombinant human ADAM9, also known as MDC9 or meltrin gamma, is a member of the ADAM family that contains "a disintegrin and metalloprotease like" domain (1,2). ADAM9 is widely expressed on the cell surface across multiple cell types and tissues where it is involved in diverse biological functions in the extracellular matrix (ECM) (2). Like other membrane-anchored ADAMs, expressed ADAM9 has a C-shaped structure that facilitates substrate recognition and cleavage and consists of a prodomain with a cysteine switch and furin cleavage sequence, a catalytic domain with the zinc binding site, along with several additional domains: a disintegrin-like domain, a cysteine-rich domain, an EGF-like domain, a transmembrane domain, and the cytoplasmic domain (2). A zinc ion in the catalytic domain of ADAM-9 coordinates with the prodomain to maintain latency. Removal of the propeptide through cleavage by proprotein convertases activates the protein (2).  ADAM9 has specificity for targets containing an established preferred consensus sequence including a broad range of substrates within the ECM such as tumor necrosis factor-alpha (TNF-alpha), growth factors and their receptors such as the p75 TNF receptor, and key molecules beta -amyloid protein precursor, c kit ligand-1, oxidized insulin beta -chain, and fibronectin (2-4). In addition to catalytic activity, ADAM9 functions as an adhesion molecule through binding of its disintegrin domain (2,5,6) and the cytoplasmic domain of ADAM9 interacts with Src homology 3 (SH3) containing proteins and protein kinase C (2,7,8). Given the broad expression and diverse activity of ADAM9, it plays an important role in pathological diseases including degenerative diseases such as Alzheimers, inflammatory diseases such as COPD and tumor biology in many cancers including lung, prostate, liver, breast, pancreatic making it attractive as a biomarker and therapeutic target (2, 9-15).

References

  1. Moss, M.L. et al. (2001) Drug Discov. Today 6:417.
  2. Chou, C.W, et al. (2020) Int. J. Mol. Sci. 21:7790. 
  3. Roghan, M. et al. (1999) J. Biol. Chem. 274:3531.
  4. Schwettmann, L. and H. Tschesche (2001) Prot. Express. & Purif. 21:65.
  5. Nath, D. et al. (2000) J. Cell Sci. 113:2319.
  6. Zhou, M. et al. (2001) Biochem. Biophys. Res. Comm. 280:574.
  7. Izumi, Y. et al. (1998) EMBO J. 17:7260.
  8. Howard, L. et al. (1999) J. Biol. Chem. 274:31693.
  9. Cong, L. and J. Jia (2011) Neurobiol. Aging 32:54.
  10. Zhang, J. et al. (2014) J. Cancer Res. Clin. Oncol. 140:1441.
  11. Hua, Y. et al. (2018) Oncol. Lett. 15:9051.
  12. Liu, R. et al. (2018) Onco. Targets Ther. 11:4065.
  13. Wang, X. et al. (2018) Am. J. Respir. Crit. Care Med. 198:1500.
  14. Xing, C. et al. (2019) Artif. Cells Nanomed. Biotechnol. 47:3920.
  15. Oh, S. et al. (2020) Cancers 12:745.

Long Name

A Disintegrin and Metalloprotease-like Domain 9

Alternate Names

MCMP, MDC9, Meltrin gamma

Entrez Gene IDs

8754 (Human); 11502 (Mouse)

Gene Symbol

ADAM9

UniProt

Q13443.1

Additional ADAM9 Products

Product Documents for Recombinant Human ADAM9 His-tag Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human ADAM9 His-tag Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.